Literature DB >> 21566223

The genomic architecture of sporadic heart failure.

Gerald W Dorn1.   

Abstract

Common or sporadic systolic heart failure (heart failure) is the clinical syndrome of insufficient forward cardiac output resulting from myocardial disease. Most heart failure is the consequence of ischemic or idiopathic cardiomyopathy. There is a clear familial predisposition to heart failure, with a genetic component estimated to confer between 20% and 30% of overall risk. The multifactorial etiology of this syndrome has complicated identification of its genetic underpinnings. Until recently, almost all genetic studies of heart failure were designed and deployed according to the common disease-common variant hypothesis, in which individual risk alleles impart a small positive or negative effect and overall genetic risk is the cumulative impact of all functional genetic variations. Early studies used a candidate gene approach focused mainly on factors within adrenergic and renin-angiotensin pathways that affect heart failure progression and are targeted by standard pharmacotherapeutics. Many of these reported allelic associations with heart failure have not been replicated. However, the preponderance of data supports risk-modifier effects for the Arg389Gly polymorphism of β1-adrenergic receptors and the intron 16 in/del polymorphism of angiotensin-converting enzyme. Recent unbiased studies using genome-wide single nucleotide polymorphism microarrays have shown fewer positive results than when these platforms were applied to hypertension, myocardial infarction, or diabetes, possibly reflecting the complex etiology of heart failure. A new cardiovascular gene-centric subgenome single nucleotide polymorphism array identified a common heat failure risk allele at 1p36 in multiple independent cohorts, but the biological mechanism for this association is still uncertain. It is likely that common gene polymorphisms account for only a fraction of individual genetic heart failure risk, and future studies using deep resequencing are likely to identify rare gene variants with larger biological effects.

Entities:  

Mesh:

Year:  2011        PMID: 21566223      PMCID: PMC3110763          DOI: 10.1161/CIRCRESAHA.110.229260

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  143 in total

1.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

Authors:  Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

2.  The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity.

Authors:  Heike Bruck; Kirsten Leineweber; Thomas Temme; Melanie Weber; Gerd Heusch; Thomas Philipp; Otto-Erich Brodde
Journal:  J Am Coll Cardiol       Date:  2005-11-04       Impact factor: 24.094

3.  Segmental copy number variation shapes tissue transcriptomes.

Authors:  Charlotte N Henrichsen; Nicolas Vinckenbosch; Sebastian Zöllner; Evelyne Chaignat; Sylvain Pradervand; Frédéric Schütz; Manuel Ruedi; Henrik Kaessmann; Alexandre Reymond
Journal:  Nat Genet       Date:  2009-03-08       Impact factor: 38.330

4.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.

Authors:  M R Bristow; R Ginsburg; V Umans; M Fowler; W Minobe; R Rasmussen; P Zera; R Menlove; P Shah; S Jamieson
Journal:  Circ Res       Date:  1986-09       Impact factor: 17.367

5.  A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor.

Authors:  D A Mason; J D Moore; S A Green; S B Liggett
Journal:  J Biol Chem       Date:  1999-04-30       Impact factor: 5.157

6.  beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.

Authors:  Steven G Terra; Daniel F Pauly; Craig R Lee; J Herbert Patterson; Kirkwood F Adams; Richard S Schofield; Bernadette S Belgado; Karen K Hamilton; Juan M Aranda; James A Hill; Hossein N Yarandi; Joseph R Walker; Michael S Phillips; Craig A Gelfand; Julie A Johnson
Journal:  Clin Pharmacol Ther       Date:  2005-03       Impact factor: 6.875

7.  Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study.

Authors:  F Cambien; F Alhenc-Gelas; B Herbeth; J L Andre; R Rakotovao; M F Gonzales; J Allegrini; C Bloch
Journal:  Am J Hum Genet       Date:  1988-11       Impact factor: 11.025

8.  Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.

Authors:  Sara L Van Driest; Vlad C Vasile; Steve R Ommen; Melissa L Will; A Jamil Tajik; Bernard J Gersh; Michael J Ackerman
Journal:  J Am Coll Cardiol       Date:  2004-11-02       Impact factor: 24.094

9.  The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure.

Authors:  M Packer
Journal:  J Am Coll Cardiol       Date:  1992-07       Impact factor: 24.094

10.  Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors.

Authors:  S S Joseph; J A Lynham; A A Grace; W H Colledge; A J Kaumann
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

View more
  17 in total

Review 1.  Clinical considerations of heritable factors in common heart failure.

Authors:  Thomas P Cappola; Gerald W Dorn
Journal:  Circ Cardiovasc Genet       Date:  2011-12

2.  Application of an F0-based genetic assay in adult zebrafish to identify modifier genes of an inherited cardiomyopathy.

Authors:  Yonghe Ding; Mingmin Wang; Haisong Bu; Jiarong Li; Xueying Lin; Xiaolei Xu
Journal:  Dis Model Mech       Date:  2022-06-23       Impact factor: 5.732

3.  Prevalence of heart failure signs and symptoms in a large primary care population identified through the use of text and data mining of the electronic health record.

Authors:  Rajakrishnan Vijayakrishnan; Steven R Steinhubl; Kenney Ng; Jimeng Sun; Roy J Byrd; Zahra Daar; Brent A Williams; Christopher deFilippi; Shahram Ebadollahi; Walter F Stewart
Journal:  J Card Fail       Date:  2014-04-04       Impact factor: 5.712

4.  A Swedish Nationwide Adoption Study of the Heritability of Heart Failure.

Authors:  Magnus P Lindgren; MirNabi PirouziFard; J Gustav Smith; Jan Sundquist; Kristina Sundquist; Bengt Zöller
Journal:  JAMA Cardiol       Date:  2018-08-01       Impact factor: 14.676

5.  Overweight, air and noise pollution: Universal risk factors for pediatric pre-hypertension.

Authors:  Roya Kelishadi; Parinaz Poursafa; Kasra Keramatian
Journal:  J Res Med Sci       Date:  2011-09       Impact factor: 1.852

6.  Transcriptome analysis reveals distinct patterns of long noncoding RNAs in heart and plasma of mice with heart failure.

Authors:  Danhua Li; Geng Chen; Jichun Yang; Xiaofang Fan; Yongsheng Gong; Guoheng Xu; Qinghua Cui; Bin Geng
Journal:  PLoS One       Date:  2013-10-29       Impact factor: 3.240

Review 7.  Genetics and heart failure: a concise guide for the clinician.

Authors:  Cecile Skrzynia; Jonathan S Berg; Monte S Willis; Brian C Jensen
Journal:  Curr Cardiol Rev       Date:  2015

Review 8.  MicroRNAs in heart failure: Small molecules with major impact.

Authors:  Georgia Kalozoumi; Magdi Yacoub; Despina Sanoudou
Journal:  Glob Cardiol Sci Pract       Date:  2014-06-18

Review 9.  Personalized medicine: caught between hope, hype and the real world.

Authors:  Marc Dammann; Frank Weber
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

10.  Cardiac dyssynchrony and response to cardiac resynchronisation therapy in heart failure: can genetic predisposition play a role?

Authors:  N Lahrouchi; C R Bezzina
Journal:  Neth Heart J       Date:  2016-01       Impact factor: 2.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.